News Archive

There’s a “No Vacancy” sign hanging out front University of Maryland, Baltimore County’s research and development park, and leaders say they have the state’s cyber security industry to thank.

University officials say the popularity of cyber security and growth in the number of young companies launching in that industry contributed to bwtech@UMBC’s popularity in recent years. The research and technology park is at capacity for the first time since it was established in 1989.

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and the College of American Pathologists (CAP), the world leader in laboratory quality assurance and improvement, today announced the launch of a new strategic alliance that will provide solutions to advance laboratory quality for improved patient outcomes in China and India. BD and CAP announced the collaboration during the American Association for Clinical Chemistry (AACC) Annual Meeting in Houston, Texas.

Laboratories play a critical role in the diagnosis and treatment of disease for the more than 2.5 billion people who live in China and India. The BD/CAP Strategic Alliance will improve access to external quality assurance/proficiency testing (PT) that can have a direct and positive impact on laboratory quality, and therefore, patient outcomes. Together BD and CAP will provide education to improve awareness of global practice standards and training that will help laboratories achieve their quality improvement goals. Additionally, BD will manage PT distribution, including sales, shipping, and first-line client service.

Research organizations in the Great Seneca Life Sciences Corridor are considering the creation of a common cyberinfrastructure that would facilitate sharing and spur innovative ideas.

Anil Srivastava, president of Open Health Systems Laboratory on Johns Hopkins University’s Montgomery County campus, proposed the idea and held a meeting Monday with physicians, university faculty and representatives from Cisco Systems, Montgomery County government, the National Institute of Standards and Technology, MedImmune and other organizations.

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, under which Kolltan will in-license a monoclonal antibody targeting the Her3 receptor tyrosine kinase from MedImmune. Based on the current program status, Kolltan anticipates initiating Phase 1 clinical testing of this product in the first quarter of 2014.

“This in-licensing opportunity exemplifies our leadership in and focus on receptor tyrosine kinases and their key role in oncology and other serious diseases,” commented Dr. Jerry McMahon, Kolltan’s President and Chief Executive Officer. “Kolltan will apply its extensive scientific expertise and R&D drug development experience to prepare for entry into the clinic, including a focus on patient selection strategies. Kolltan is excited to advance this innovative product candidate into clinical testing for the broad potential treatment of cancer patients where this target plays a role.”

Maryland’s venture capital fund has announced that two tech companies in the state will get a total of $350,000.

Gov. Martin O’Malley made the announcement on Monday.

A Baltimore firm called SocialToaster has received approval for $200,000. The company specializes in social media and customer engagement.

A new class of medicines could give doctors the ability to awaken underperforming genes in patients who currently have no treatment options.

Boston-area startup RaNA Therapeutics is developing a novel kind of medicine that can boost the activity of genes that may be silenced or underactive and thus cause disease. The medicine would use a small RNA-like molecule that blocks the function of a long RNA molecule that is hampering the expression of such a gene.

Becton, Dickinson and Company is one of domain players of insulin syringes and other delivery devices, referring to the pie chart, Market Shares of the leading suppliers of Insulin Syringes and other delivery devices, 2009. Today, the market shares accounts 45% in the world, 80% in U.S. and Europe .

Medtronic has entered into an innovative partnership with The Johns Hopkins University, agreeing to provide $200,000 a year for up to three years and skilled mentoring to help biomedical engineering students design new healthcare solutions for underserved patients in developing countries.

The partnership was announced recently by Omar Ishrak, Medtronic’s chairman and chief executive officer, during his keynote address at the university’s annual Biomedical Engineering Design Day event. During his talk, Ishrak called attention to the need to improve access, outcomes, and the efficiency of healthcare solutions in developing regions of countries such as India, China, and Brazil.

QIAGEN N.V. announced a partnership with Exosome Diagnostics Inc. to develop and commercialize high-performance sample preparation kits for the processing of nucleic acids from exosomes.

According to a release, combining the Exosome Diagnostics platform technology approach with select QIAGEN consumables and automation platforms has the potential to allow researchers, drug developers and doctors to take repeated, real-time genetic “snapshots” of disease from patients’ blood, urine or cerebrospinal fluid without the need for tissue biopsy. The companies are targeting initial product launches in the first half of 2014. Financial terms were not disclosed.